--24. The liposomal formulation according to claim 23, which comprises a mixture of populations of particles with diameters respectively bigger than 400 nm and lower than 100 nm.--

--25. A process for the preparation of a plurality of distinct populations of liposomal formulations of particles with distinct mean diameters containing one dinitroaniline, which comprises the steps:

(1) obtention of the liposomal formulations containing vesicles of dinitroaniline by hydration, with a solution containing an antisublimating agent of a lipidic film containing the dinitroaniline;

(2) lyophilization of the dinitroaniline liposomal formulations; and

(3) rehydration of the dehydrated liposomal formulations.--

--26. The process according to claim 25, which comprises performing a sizing step of the dinitroaniline liposomal formulation in order to reduce the vesicle's diameter, done previously to the dehydration step.--

--27. The process according to claim 26, which comprises performing the sizing step by extrusion of the vesicles under

pressure through porous membranes.--

--28. The process according to claim 25, wherein the hydration is carried out by the addition of a small amount of an aqueous solution, followed by the addition of the remaining volume of the aqueous solution, after a resting period.--

--29. The process according to claim 28, which comprises using, in the hydration steps, a non-saline solution.--

--30. The process according to claim 29, which comprises performing the rehydration steps with saccharose, trehalose, glucose or any other sugar solution.--

--31. The process according to claim 25, which comprises mixing at least two different distinct mean diameter particle populations.--

--32. The process according to claim 31, which comprises mixing particles after sizing to yield a population of particles with diameters of, respectively, bigger and lower than 100 nm.--

--33. The process according to claim 32, which comprises performing the sizing step by extrusion of vesicles under pressure through a porous membrane.--

--34. The process according to claim 31, which comprises performing the hydration by addition of a small amount of aqueous solution, followed by addition of the rest of the volume after a rest period.--

--35. The process according to claim 31, which comprises using in the hydration step a non-saline solution.--

--36. The process according to claim 31, which comprises performing rehydration using solutions of saccharose, trehalose, glucose or another sugar.--

--37. The process according to claim 31, which comprises using at least one of the lipids selected from the group consisting of distearoylphosphatidylcholine (DSPC), phosphatidylcholine (PC), cholesterol (Chol) or derivatives, sphingomielin (SM), dioleoylphosphatidylcholine (DOPC), dioleoylphosphatidylglycerol (DOPG), phosphatidylglycerol (PC), dimiristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), gangliosides, ceramides, phosphatidylinositol (PI), phosphatydic acid (PA), dicetylphosphate (DcP), dimiristoylphosphatidylglycerol (DMPG), stearylamine (SA), dipalmitoylphosphatidylglycerol (DPPG) and mixtures thereof.--

--38. The process according to claim 31, wherein the dinitroaniline comprises trifluralin.--

--39. A liposomal formulation according to claim 23, when prepared by the process according to claim 25.--

--40. A method of using the liposomal formulation according to claim 23 for the treatment of disease in humans or animals, which comprises administration of a therapeutic quantity of the dinitroaniline liposomal formulation to humans or animals.--

Attached hereto is a marked-up version of the changes made to the application by this Amendment.